High-level expression of AmpC β-lactamases results in organisms resistant to multiple β-lactam antibiotics. The mechanism of chromosomally mediated AmpC resistance has been elucidated, however the mechanism(s) driving plasmid-encoded AmpC resistance are unknown. Studies were designed to identify factors which influence expression of plasmid-encoded ampC genes and correlate these factors with resistance. As the model system, ampC genes of Enterobacter origin were used to determine how gene copy number, genetic background and genetic organization influenced resistance phenotypes. To this end, gene expression from the plasmidencoded inducible bla ACT-1 and non-inducible bla MIR-1 were compared with chromosomal ampC gene expression from both wild-type (WT) and derepressed Enterobacter cloacae isolates. RNA levels within the original clinical isolates were examined using primer extension analysis, whereas a new PCR strategy was developed to examine gene copy number. These data revealed that bla ACT-1 and bla MIR-1 constitutive expression was 33-and 95-fold higher than WT expression, whereas copy numbers of the plasmid-encoded genes were 2 and 12, respectively. Differences in promoters and transcriptional starts for the respective plasmid-encoded genes were noted and contribute to increases observed in overall expression. Finally, β-lactam MICs were increased two-to 16-fold when bla ACT-1 was expressed in Escherichia coli AmpD -strains compared with E. coli AmpD + strains. In conclusion, high-level expression of plasmid-encoded ampC genes requires interplay between multiple factors including genetic organization, promoter modifications, genetic background, and to some extent gene copy number. In addition, clinical laboratories need to be aware that genetic backgrounds of inducible plasmid-encoded genes can dramatically influence MICs for organisms not normally associated with derepressed phenotypes.
Introduction
The mechanism of chromosomal AmpC-mediated resistance in Gram-negative organisms is high-level expression of the AmpC β-lactamase. Organisms expressing high levels of AmpC β-lactamases can be resistant to almost all β-lactam drugs except cefepime, cefpirome and the carbapenems. 1 ampC genes were first identified on the chromosomes of several genera of Gram-negative organisms including Enterobacter spp., Citrobacter freundii, Morganella morganii, Hafnia alvei, Serratia marcescens and Escherichia coli. [2] [3] [4] [5] [6] All these organisms, except E. coli, encode an inducible chromosomal ampC β-lactamase gene. 3 Induction of the ampC gene requires three additional gene products, AmpG, AmpD and AmpR, in addition to an inducing agent, such as cefoxitin or imipenem. 7 AmpG is a permease that allows entry of muropeptides into the cytoplasm from the periplasmic space as part of the cell wall recycling pathway. [7] [8] [9] In excess, these muropeptides act as cofactors in the induction process in which the amidase, AmpD, fails to process all the muropeptides that enter the cytosol. 7, 10, 11 AmpR is a DNA binding protein required for regulation of chromosomal ampC gene expression. 3, [12] [13] [14] The discovery of the AmpC β-lactamase, CMY-1, in 1989 was the first published report of a plasmid-encoded AmpC β-lactamase. 15 Since then, over 20 plasmid-encoded AmpC β-lactamases have been reported in several genera of bacteria (genetic backgrounds) including Salmonella spp., E. coli, Proteus mirabilis and Klebsiella pneumoniae. [15] [16] [17] [18] Most of these plasmid-encoded genes lack the ampR gene and therefore do not display an inducible AmpC phenotype. However, since 1998, three inducible plasmid-encoded AmpC β-lactamases have been reported. Two of these genes, bla DHA-1 and bla DHA-2 are of M. morganii origin, whereas the most recently discovered gene, bla , is of Enterobacter origin. [18] [19] [20] [21] These ampC genes are linked to an ampR gene that is transcribed divergently from ampC. This genetic organization is identical to that observed for inducible chromosomal ampC genes.
Mutations associated with AmpD lead to constitutive highlevel expression (derepression) of the chromosomal ampC gene in clinical isolates resulting in high-level expression of the AmpC β-lactamase. 10 Although the general mechanism for high-level expression of chromosomal ampC genes is understood, the same cannot be said for the plasmid-encoded ampC genes. Several factors could contribute to the highlevel expression of these genes. These factors include gene copy number, the genetic background of the organism and the genetic organization or context of the genetic locus from which the genes are expressed. It has been suggested that two factors may contribute to high-level expression from plasmid-encoded ampC genes in the absence of AmpR. These factors include expression from high-copy number plasmids 22 and the absence of regulation by AmpR, in which ampC gene expression has been observed to increase 2.5-to 5.8-fold. 4, 12 However, the contributions of increases in ampC transcription and high copy number in the high-level expression of plasmid-encoded ampC genes have not been documented. The data presented in this paper correlate the overall gene expression from four ampC genes of Enterobacter origin in clinical isolates, with gene copy number, genetic organization and genetic background. These genes include the non-inducible plasmid-encoded ampC gene bla MIR-1 , the inducible plasmid-encoded ampC gene bla ACT-1 , both expressed in K. pneumoniae isolates, and two chromosomal ampC genes expressed in Enterobacter cloacae, one inducible and one exhibiting high-level constitutive expression (derepressed).
Materials and methods

Bacterial strains
The clinical isolates and bacterial strains used in this study are listed in Table 1 .
Primer extension analysis
Total RNA was isolated from Mueller-Hinton broth (MHB) (Oxoid, UK) using modified Trizol (Invitrogen, Carlsbad, CA, USA). Briefly, 6 h 15 mL cultures were diluted 1:20 (100 mL total volume) in fresh pre-warmed MHB and allowed to grow to an OD 600 of 0.65 at 37°C with shaking at 100 rpm. These cells represent the early log phase of growth. Cells were collected in pre-chilled centrifuge tubes and the cell pellet was suspended in 1 mL of modified Trizol solution. Induction assays using cefoxitin and primer extension analysis were carried out as previously described. 20 Fifty micrograms of total RNA was used for each primer extension reaction for ampC transcripts whereas 1 µg was used for the 16S rRNA reactions. The primers for primer extension analysis are listed in Table 2 .
β-Lactamase hydrolysis assays
Hydrolysis assays for each of the four clinical isolates were carried out as described previously using 100 µM cefalothin as substrate. 20, 23 Enzyme was recovered from the same cultures used for RNA isolation.
MIC determinations
The susceptibility profiles were determined by agar dilution according to National Committee for Clinical Laboratory Standards (NCCLS) methods. 24 The antimicrobial agents were obtained from different sources. Imipenem was obtained from Merck (Rahway, NJ, USA); cefotaxime and piperacillin were obtained from Sigma Chemical Co. (St Louis, MO, USA); ceftazidime was obtained from GlaxoSmithKline (Collegeville, PA, USA); cefpodoxime was from Pharmacia and Upjohn (Kalamazoo, MI, USA); cefepime and aztreonam were from Bristol-Myers Squibb (Princeton, NJ, USA); cefixime was from Wyeth-Ayerst Lederle (Bound Brook, NJ, USA).
Copy number determination
Comparative PCR was used to obtain a ratio of band intensities between a single copy chromosomal gene, in this case ampD, and the gene of interest, ampC. ampD is a single copy gene, as verified by BLAST analysis of the E. coli and K. pneumoniae genomes. 25 PCRs were carried out as previ-ously described. 26 Primers used for copy number determinations are indicated in Table 2 . Ten-fold serial dilutions, ranging from 10 0 to 10 -5 , of total DNA prepared from each isolate served as templates for PCR. The PCR products were separated on a 0.8% agarose gel, stained with Vistra Green (Amersham Pharmacia, Piscataway, NJ, USA), and visualized with a Storm Molecular Imager (Molecular Dynamics Inc., Sunny, CA, USA). Quantification of the bands was carried out with ImageQuant software (Molecular Dynamics Inc.). A ratio was determined by comparison of band intensities between the PCR products of the target gene, ampC and the single copy gene, ampD. These ratios were determined between band intensities obtained from PCR products amplified from the same dilution of template (normally the 10 -3 dilution), which was within the linear range of the PCR cycle. The initial copy number was verified by diluting the PCR product from the diluted template (10 -3 dilution) by the calculated ampC to ampD ratio. The diluted PCR product and the undiluted ampD PCR product from the original diluted (10 -3 ) template were visualized as described above. Initial copy number was verified when the peak intensities for each band were equivalent between the diluted target ampC gene product and the undiluted single copy ampD product (see text for further explanation).
Cloning and transformation
bla ACT-1 and bla MIR-1 were amplified by PCR as described above using Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA). Amplicons were visualized on a 0.8% agarose gel with Crystal Violet staining. DNA was extracted from the gel using a SNAP column (Invitrogen, Carlsbad, CA, USA) and ligated into the pCR-TOPO-XL cloning vector and transformed into E. coli Top10 competent cells (Invitrogen). The amplicons were subcloned into pACYC184 as an EcoRI fragment. 27 The resulting plasmids were isolated and electroporated into E. coli Top10 (Invitrogen), E. coli SNO302 and E. coli JRG582 (Tables 1 and 3 ). The plasmid DNA from 
these clones was sequenced as described previously using the primers in Table 2 to verify the insert sequences. 20
Results
ampC RNA expression
Primer extension and hydrolysis data confirmed the induction phenotypes of E. cloacae 55, K. pneumoniae 225, K. pneumoniae 96D and E. cloacae V204. These four isolates represent ampC β-lactamase gene expression of Enterobacter origin in different genetic backgrounds (Table 1 ). In addition, primer extension analysis was carried out to determine the relative amounts of steady-state ampC RNA expressed from each clinical isolate tested. As determined previously by primer extension analysis, bla ACT-1 was induced five-fold over constitutive levels when RNA expression was analysed 15 min post-induction, whereas β-lactamase hydrolysis assays indicated a 1.3-fold induction (Figure 1 ). 20 β-Lactamase hydrolysis assays showed that wild-type (WT) E. cloacae AmpC was also induced, whereas both MIR-1 and E. cloacae V204 (derepressed mutant) AmpC were uninducible ( Figure  1 ). These induction phenotypes were also reflected at the RNA level (data not shown). However, when basal (noninduced) level RNA expression between these four strains was examined, there was a 33-, 95-and 75-fold difference between WTampC and bla ACT-1 , bla MIR-1 and DRampC, respectively (Figure 2a and b) .
Gene copy number
In contrast to the predicted 2.5-to 5.8-fold increase in the absence of ampR for plasmid-encoded ampC genes, differences of 33-(ampR present) and 95-fold increases (ampR absent) over chromosomal ampC expression were observed (Figure 2a and b) . However, the constitutive level of RNA expression between the two plasmid-encoded ampC genes, bla ACT-1 and bla MIR-1 was only three-fold. These data indicated a difference in the regulation of constitutive expression between the plasmid-encoded AmpC β-lactamase genes compared with each other and WTampC. One explanation for the large increase in overall RNA expression from the plasmid-encoded genes could be gene copy number. Therefore, the copy number of each of these genes was determined by a comparative analysis using PCR. A ratio was determined between amplified products of the ampC gene in question and the single copy chromosomal gene, ampD (Figure 3 ). PCR amplification of each ampC gene and the respective ampD gene for each organism (K. pneumoniae or E. cloacae) was carried out using 10-fold serial dilutions of template DNA (10 0 -10 -5 ) from each bacterial strain (Figure 3a and c) . The band intensities of the ampC and ampD amplified products from the 10 -3 template dilutions (Figure 3a and c) are represented by the graphs in Figure 3(b and d) . The area under the curve for each peak was used to determine the ratio of ampli- fied products of bla ACT-1 to ampD (Figure 3b ) and bla MIR-1 to ampD (Figure 3d ). The amount of bla ACT-1 and bla MIR-1 products with respect to the ampD genes revealed a ratio of 2 (Figure 3a and b) and 12 ( Figure 3c and d) , respectively.
Verification of these numbers was obtained by diluting the bla ACT-1 and bla MIR-1 PCR products from the 10 -3 reaction (Figure 3a for bla ACT-1 and 3c for bla MIR-1 ) by factors of 2 and 12, respectively, and measuring the amount of the diluted ampC products (Figure 3e and f) compared with the undiluted ampD products for each strain. The areas under the curve in Figure 3 (e and f) represent the intensities of the band obtained from the bla ACT-1 PCR amplicons diluted 1:2, and the undiluted ampD amplicon. As shown in Figure 3 (e), the 1:2 diluted band intensity was now equivalent to the area under the curve detected for the ampD product.
Similarly, comparing the band intensities for the 1:12 dilution of the bla MIR-1 10 -3 PCR product and the undiluted 10 -3 ampD product, the area under the curve was equivalent (Figure 3f) . Therefore, the copy number of the inducible plasmid encoded bla ACT-1 is 2, whereas the copy number of the non-inducible plasmid encoded bla MIR-1 is 12. This method was also used to verify the copy numbers of the chromosomal ampC genes from E. cloacae 55 and V204, which were both one (data not shown). As a control for the technique, bla ACT-1 and bla MIR-1 were cloned into the vector pACYC184 which has a copy number of 10 to 12. 27 The copy number of both bla ACT-1 and bla MIR-1 cloned into pACYC184 was determined to be 11 for each gene (data not shown). These data indicate that the copy number protocol designed in this study is an accurate method for determining relative gene copy number.
Promoter sequence and expression comparisons
Primer extension data were used to map the transcriptional start sites for the mRNA transcript of each gene studied (Figures 2a and 4) . As expected, the bla ACT-1 mapped to the guanosine at position +1 (Figure 4 ), 50 bp upstream of the ATG start codon. 20 The start site of transcription for the E. cloacae chromosomal ampC genes, WTampC and DRampC was a cytosine at the position identical to the bla ACT-1 transcriptional start site. Surprisingly, the transcriptional start site of bla MIR-1 mapped to the cytosine at position -36 relative to the transcript start sites for bla ACT-1 and chromosomal ampC genes (Figure 4 ), 89 bp upstream of the ATG start codon. Putative -10, TAaAtT, and -35, TTGAat, promoter elements having similarity to the E. coli σ70 promoter consensus sequences -10, TATAAT and -35, TTGACA were identified. The spacing between these putative sites was 17 bp, the optimal distance between these two elements for maximal expression as described for E. coli. 28 The relative level of expression from each promoter was determined by primer extension analysis using clones E. coli WTpACT-1 and E. coli WTpMIR-1 (Table 1) . These clones comprise the native promoter in addition to the structural gene cloned into pACYC184. RNA levels expressed from the same vector were only slightly increased (1.6-fold) for E. coli WTpMIR-1 when compared with RNA expression from E. coli WTpACT-1 (data not shown).
β-Lactam MIC levels for AmpD -E. coli
Constitutive high-level expression (derepression) of the chromosomal ampC gene of E. cloacae V204 gave a 75-fold increase in expression and significant increases in β-lactam MICs (Figure 2b and Table 3 ). In contrast, the WT strain, E. cloacae 55, expressing an inducible chromosomal ampC gene does not exhibit high β-lactam MICs. However, the susceptibility profile of an organism expressing an inducible plasmid-encoded ampC gene in an AmpD -background is unknown. Therefore, β-lactam MICs were determined for E. coli strains that were either AmpD + or AmpD -expressing either ACT-1 or MIR-1. Under these conditions, the β-lactam MICs increased two-to 16-fold in AmpD -E. coli expressing ACT-1 when compared with AmpD + E. coli expressing ACT-1, whereas the β-lactam MICs for E. coli ∆DpMIR-1 did not change from those for E. coli WTpMIR-1 for any drug tested ( Table 3) . As indicated in Table 3 , the β-lactam MICs observed for E. coli WTpACT-1 were within one dilution of those for both E. coli WTpMIR-1 and E. coli ∆DpMIR-1.
Discussion
AmpD mutations have been associated with constitutive high-level ampC expression (derepression) and increases in cephalosporin MICs for organisms encoding inducible chromosomal ampC β-lactamase genes. 7 These mutations occur spontaneously in every 10 3 -10 7 bacterial cells. 29, 30 AmpD functions in the cell wall recycling pathway making it a necessary component of other Gram-negative organisms. However, AmpD mutants in clinical isolates of E. coli, K. pneumoniae, Salmonella spp. and other bacterial strains have not been documented because no phenotype can differentiate these mutants from WT cells due to the lack of an inducible chromosomal ampC gene. These studies have demonstrated that ACT-1 expressed in an AmpD -background results in an increase in β-lactam MICs of two-to 16-fold. This effect was not observed for the non-inducible plasmid-encoded ampC gene, bla MIR-1 . Clinical laboratories should be aware of the possibility of phenotypically 'derepressed' E. coli, K. pneumoniae, Salmonella spp. and other Gram-negative strains expressing inducible plasmid-encoded AmpC β-lactamases and the concomitant increase in β-lactam MICs associated with this genotype.
In addition to correlating β-lactam MICs with ampC expression, this study aimed to determine what factors influence high-level expression of plasmid-encoded ampC genes of Enterobacter origin by correlating in vivo constitutive ampC expression levels with copy number and genetic characteristics. In studies using cloned ampC/ampR constructs expressed in E. coli, in the absence of AmpR, ampC expression was shown to increase 2.5-to 5.8-fold. 4, 12 Until recently, all plasmid-encoded ampC genes described in the literature were not associated with an ampR gene. Therefore, it was predicted that expression from a plasmid-encoded ampC gene, in the absence of AmpR, would increase 2.5-to 5.8-fold. However, using primer extension, this study demonstrated that bla MIR-1 , a plasmid-encoded ampC gene expressed in the absence of AmpR, exhibited a 95-fold increase in expression relative to WTampC. These expression levels are 16-to 38-fold higher than the amount of expression previously reported using reporter gene assays in E. coli or cloning these genes into vectors such as pACYC184. 12 These data indicate that the level of plasmid-encoded ampC expression in clinical isolates lacking AmpR is not due simply to a release from repression by AmpR. Furthermore, for constitutive bla ACT-1 expression, a 33-fold increase in expression was observed ( Figure 5 ). This level of expression was in contrast to what might be predicted based on the genetic arrangement of the plasmid and its correlation with chromosomal ampC genes.
The differences observed in the relative amounts of RNA expression between bla ACT-1 and bla MIR-1 suggested that other factors played a role in the overall expression of these genes. It has been suggested that high-level expression of plasmidencoded ampC β-lactamase genes results from the gene being encoded on high copy number plasmids. 22 However, no evidence has been published to substantiate or refute this hypothesis. The copy number of bla ACT-1 was 2, and demonstrated that high-level expression of plasmid-encoded ampC genes does not need to be mediated by high copy number plasmids. However, a moderate copy number (12) of the plasmid encoding bla MIR-1 was present in the clinical isolate K. pneumoniae 96D. 31 These data indicated that multiple mechanisms are involved in the high-level expression of plasmid-encoded ampC genes.
Contribution of copy number to overall gene expression was analysed in the four clinical isolates expressing ampC genes of Enterobacter origin by comparing the ratio of constitutive expression with gene copy number ( Figure 5 ). The expression per copy number ratio for bla MIR-1 is 8, whereas for bla ACT-1 it is 17. The similarities between the genetic context of bla ACT-1 and the WTCampC would predict that the copy number for bla ACT-1 would be the same as the relative fold increase in expression, i.e. 33-fold. This was not the case as the copy number of bla ACT-1 is two, yielding an expression per copy number ratio of 17. These data indicate that copy number does not account for the difference observed in expression levels between bla ACT-1 and WTCampC. When the promoter regions of bla ACT-1 and WTampC were compared, only three mutations were observed. The most significant mutation occurred in the putative -10 promoter element of bla ACT-1 . This mutation was located at position -9 and resulted in a C to T transition, which increased the similarity of the bla ACT-1 promoter to the E. coli -10 consensus sequence TATAAT (Figure 4) . 20 This same substitution in E. coli ampC promoters has been shown to increase expression seven-to 20-fold. 32, 33 Thus, these data indicate that the point mutation in the bla ACT-1 promoter contributes to the increased expression observed for bla ACT-1 transcription compared with wildtype expression.
The expression to copy number ratio of 8 for bla MIR-1 was surprising. Copy number has been implicated as the major mechanism to explain the increase in AmpC β-lactamase activity when the gene is encoded by a plasmid. 22 This hypothesis would predict that the overall expression of bla MIR-1 would be six-fold higher than bla ACT-1 . However, the difference in total RNA expression between the two genes was only three-fold. In addition, this same hypothesis would predict that the copy number difference observed between the two genes would be three-fold not six-fold. Furthermore, comparisons between promoter expression of bla MIR-1 and bla ACT-1 in E. coli when the genes were encoded by the same vector indicated that the difference in expression levels was less than two-fold. These data support the expression to copy number ratio for bla MIR-1 being less than the bla ACT-1 ratio and indicate that not all the plasmid copies of bla MIR-1 may participate equally in the overall expression. In addition to the expression to copy number ratio, the location of the start site of bla MIR-1 transcription was unique compared with other Enterobacter ampC genes. Mapping the bla MIR-1 start site to position -36, relative to the transcript start sites for bla ACT-1 and chromosomal ampC genes, indicated that the putative -10 position correlates to TAAATT (Figure 4 ). This -10 element also has higher similarity to E. coli consensus than the -10 elements of the E. cloacae chromosomal ampC genes. These data indicate that ampC promoter mutations may be necessary to obtain high levels of β-lactamase gene expression. In addition, the creation of new promoters upon insertion of ampC genes in the plasmid may be necessary to drive expression levels required for resistance.
In summary, the mechanism of plasmid-encoded AmpC β-lactamase resistance is multifaceted and probably fluctuates depending on the genetic organization and background in which these genes are expressed. This will make 'predicting' the β-lactam MIC values for a particular plasmid-encoded AmpC β-lactamase somewhat 'unpredictable' and incredibly challenging. 
